TWST News

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its antibody production and characterization portfolio with the launch of Twist Express Screening Antibodies, a high-throughput cell-free offering that delivers purified full-length IgG with SPR...

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced that it will issue its financial results for the fiscal 2026 fourth quarter and full year ended September 30, 2026, before the opening of the market on November 12, 2026. The company plans to...

Ark's latest quarterly report shows that several stocks made meaningful contributions across multiple ETFs.

Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.

Twist Bioscience (NASDAQ:TWST) has outperformed the market over the past 5 years by 3.68% on an annualized basis producing an average annual return of 15.78%. Currently, Twist Bioscience has a market capitalization ofread more...

Twist’s Lilly agreement and involvement in Anthropic research highlight its role in building and testing AI-designed proteins.

AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment AI Drug Discovery Forecasts Vary Widely as Sector Shifts to DeploymentPR NewswireAUSTIN, Texas, Oct. 1, 2026Equity Insider News CommentaryAUSTIN, Texas, Oct. 1, 2026 /PRNewswire/ --Towards Healthcare projects that the global AI...

Biotech and life-science stocks are commanding attention as a fresh wave of momentum sweeps through the sector, with Silexion Therapeutics (NASDAQ:SLXN), Kraig Biocraft Laboratories (OTCQB:KBLB), 10x Genomics (NASDAQ:TXG), Moderna (NASDAQ:MRNA), AbCellera Biologics (NASDAQ:ABCL), Viatris (NASDAQ:VTRS), and Twist Bioscience (NASDAQ:TWST) among today’s notable names.

Twist Bioscience shares are trading lower Friday, pulling back after touching a fresh 52-week high near $192 earlier in the session.read more...